Ozone-oxidative preconditioning prevents doxorubicin-induced cardiotoxicity in sprague-dawley rats
SQUMJ-Sultan Qaboos University Medical Journal. 2014; 14 (3): 313-319
in English
| IMEMR
| ID: emr-159442
ABSTRACT
Induced dilated cardiomyopathy is the main limitation of the anti-cancer drug doxorubicin, which causes oxidative stress and cardiomyocyte death. As ozone therapy can activate the antioxidant systems, this study aimed to investigate the therapeutic efficacy of ozone-oxidative preconditioning against doxorubicin-induced cardiotoxicity. The study was carried out from September 2013 to January 2014. Sprague-Dawley rats were randomly distributed in the following treatment groups Group 1 were treated with 2 mg/kg intraperitoneal [i.p.] of doxorubicin twice a week for 50 days; Group 2 were treated with 0.3 mg of ozone/oxygen mixture at 50 micro g/ mL of ozone per 6 mL of oxygen by rectal insufflation and then treated with doxorubicin; Group 3 were treated as Group 2 but only with the oxygen, and Group 4 were treated with oxygen first, and then with sodium chloride i.p. as the control group. The results showed that ozone therapy preserved left ventricle morphology which was accompanied by a reduction of serum pro-brain natriuretic peptide levels. The cardioprotective effects of ozoneoxidative preconditioning were associated with a significant increase [P <0.05] of antioxidant enzymes activities and a reduction of lipid and protein oxidation [P <0.05]. Ozone-oxidative preconditioning prevents doxorubicin-induced dilated cardiomyopathy through an increase of antioxidant enzymes and a reduction of oxidised macromolecules. This establishes the background for future studies to determine if ozone therapy can be used as a complementary treatment for attenuating doxorubicin-induced cardiotoxicity in cancer patients
Search on Google
Index:
IMEMR (Eastern Mediterranean)
Language:
English
Journal:
Sultan Qaboos Univ. Med. J.
Year:
2014
Similar
MEDLINE
...
LILACS
LIS